e range of regulatory support activities including high level consulting re: regulatory strategy, IND completion, report generation and regulatory submission reviews. For more information, contact: Robert Burford, Ph.D., VP Regulatory Services Group, Laureate Biopharmaceutical Services Inc., at (609) 919-3332, or email Robert.Burford@LBioS.com
, or visit www.LBioS.com
About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC. For more information, please visit www.LBioS.com.
About Saints Capital, LLC
Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit
Page: 1 2 3 Related biology technology :1
|SOURCE Laureate Biopharmaceutical Services, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)2
. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility3
. FDA Approves New Device to Treat Brain Aneurysms4
. European Commission Approves DuPont Tender Offer to Acquire Danisco5
. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test6
. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri7
. FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy8
. European Union Approves Maize with Herculex® I/Herculex® RW and Herculex® RW/ Herculex® I/Roundup Ready® Corn 2 Trait Stacks for Import, Food, Feed & Processing9
. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests10
. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer11
. FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)